Purchase Order SPE2DS24P1185

Award Date 6/18/24
Potential Completion Date 6/24/24
Potential Value $4.7K
Federal Agency
Medical Supply Chain
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Seattle, WA 98109, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
6
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $5,508,014.60, was issued by the Medical Command (MEDCOM) to Inbios International Inc., a minority-owned, for-profit biotechnology company based in Seattle, Washington. The contract is for Information and Communications Technology (ICT) Development on a Cost-Plus-Fixed-Fee (CPFF) basis, with a completion date of July 20, 2019. Inbios, a Subchapter S Corporation, is a manufacturer of immunodiagnostic devices for infectious diseases. This contract award...
This federal contract award to Inbios International Inc., a minority-owned business based in Seattle, Washington, was issued by the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). The $749,998 firm fixed-price contract supports research and development (R&D) of an antibody diagnostic for COVID-19. The contract was issued under a Broad Agency Announcement (BAA) solicitation from ASPR's Division of...
This is a $12,670,301.06 firm fixed-price definitive contract awarded by the U.S. Department of Health and Human Services (DHHS) Biomedical Advanced Research and Development Authority (BARDA) to Inbios International, Inc., a minority-owned, for-profit biotechnology company based in Seattle, Washington. The contract is for the production capacity expansion of COVID-19 diagnostic tests and was awarded under Contracting Opportunity FA7013-20-S-0002, which did not have a set-aside designation....
This is a federal contract award to Inbios International Inc., a minority-owned, for-profit biotechnology company based in Seattle, Washington. The contract, awarded by the Medical Command (MEDCOM) agency of the U.S. Department of Defense, is for ICT (Information and Communications Technology) development on a Cost-Plus-Fixed-Fee (CPFF) basis. The contract has a ceiling value of $1,724,742.02 and an ultimate completion date of September 18, 2019. The contract is not set-aside and was awarded...
This federal contract award, HHSD2002017M93163P, was made by the Centers for Disease Control and Prevention (CDC) to Inbios International Inc., a minority-owned, for-profit biotechnology company based in Seattle, Washington. The $198,492.00 firm fixed-price purchase order is for INBIOS EQUIPMENT, with an ultimate completion date of July 14, 2017. The contract was awarded on March 9, 2017, and was not set aside for any specific business type. Inbios International is a key partner to multiple...
This federal contract award by the Centers for Disease Control and Prevention (CDC) is for the procurement of ELISA detection kits from Inbios International Inc., a minority-owned, for-profit biotechnology company based in Seattle, Washington. The contract, valued at $85,485.00, is a firm fixed-price purchase order with an ultimate completion date of April 30, 2020. Inbios is a critical partner to the government, particularly during the COVID-19 pandemic, having secured numerous contracts with...
The Department of State Bureau of East Asian and Pacific Affairs awarded a firm fixed-price purchase order to Inbios International Inc., a minority-owned, for-profit biotechnology company based in Seattle, Washington, for $143,218.00. The contract is for the supply of CDC 7553.0/ELISA detection kits, which are immunodiagnostic devices used for infectious disease testing. Inbios has a history of federal contract awards and grants related to the development and manufacture of diagnostic tests,...
This is a federal contract award to Inbios International Inc., a minority-owned, for-profit biotechnology company based in Seattle, Washington. The contract, awarded by the U.S. Army Medical Command (MEDCOM), is for a Small Business Innovation Research (SBIR) Phase II project, valued at $891,867.91. The contract is a Definitive Contract with a Cost Plus Fixed Fee pricing type, and the ultimate completion date is January 14, 2020. Inbios International Inc. is a specialized manufacturer of...
This is a $2,596,000.00 definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Inbios International Inc., a minority-owned, for-profit biotechnology company based in Seattle, Washington. The purpose of this firm-fixed-price contract is to procure over-the-counter (OTC) COVID-19 tests. The contract has an ultimate completion date of February 15, 2023 and was awarded on December 7, 2022. No set-aside designation was used for...
This federal contract award, W81XWH15P0522, was made by the U.S. Medical Command (MEDCOM) to Inbios International Inc., a minority-owned, for-profit biotechnology company based in Seattle, Washington. The $95,000.00 firm fixed-price purchase order contract was set aside for small businesses and has an ultimate completion date of October 15, 2015. The contract is for NORO-RD products, which likely refers to diagnostic devices or related medical technology. Inbios International is a critical...

This federal contract award, valued at $4,708.00, was issued by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to Inbios International Inc., a minority-owned biotechnology company based in Seattle, Washington. The contract is for the procurement of "TEST KIT,VISCERAL L" and has a completion date of June 24, 2024.

Inbios International Inc. is a veteran-owned, for-profit organization that specializes in the design, development, and manufacture of immunodiagnostic devices for infectious diseases. The company has a significant history of providing critical testing products and research services to various federal agencies, including the Department of Health and Human Services, the Defense Health Agency, and the Centers for Disease Control and Prevention. Through this contract, Inbios will continue to support the government's efforts to address public health challenges, such as the ongoing COVID-19 pandemic and the need for advanced diagnostic solutions.

The contract does not have a set-aside designation, indicating that it was awarded through open competition. Inbios International Inc. has also received numerous federal grants, including from the National Institute of Allergy and Infectious Diseases, to support its research and development efforts in the areas of Chagas disease, Ebola, and other emerging pathogens.

Generated 9/17/24, 10:12 AM